Please Wait

Applying Filters...

Drug Product Composition: Sumatriptan

Sumatriptan

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

51 API Suppliers, 26 USDMF, 15 CEP/COS, 4 JDMF, 13 EU WC, 6 KDMF, 20 NDC API, 26 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

5 Drugs in Development

5 Drugs in Development

INTERMEDIATES

5 Intermediates Suppliers

5 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

386 FDF Dossiers, 97 FDA Orange Book, 212 Europe, 28 Canada, 15 Australia, 19 South Africa, 15 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;SUBCUTANEOUS - EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML), INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 100MG BASE, TABLET;ORAL - EQ 25MG BASE, TABLET;ORAL - EQ 50MG BASE, SYSTEM;IONTOPHORESIS - EQ 6.5MG BASE/4HR, POWDER;NASAL - EQ 11MG BASE, SPRAY;NASAL - 20MG/SPRAY, SPRAY;NASAL - 5MG/SPRAY, TABLET;ORAL - 500MG;EQ 85MG BASE, TABLET;ORAL - 60MG;EQ 10MG BASE, INJECTABLE;SUBCUTANEOUS - EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML), INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

RELATED EXCIPIENT COMPANIES

1 Actylis, 1 Finar

EXCIPIENTS BY APPLICATIONS

1 Parenteral, 1 Topical

DIGITAL CONTENT

2 DATA COMPILATION #PharmaFlow, 34 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions, 178 Finished Drug Prices, 8 Annual Reports

MARKET PLACE

11 APIs, 1 FDF Dossiers

PATENTS & EXCLUSIVITIES

51 US Patents, 10 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM, 3 USP, 5 Others

$ Xls

Filters

Xls

USFDA APPLICATION NUMBER - 206099 / DOSAGE - POWDER;NASAL - EQ 11MG BASE

Drug Product Composition: Sumatriptan

Sumatriptan

Sumatriptan

ACCESS ALL DATA

Browse all information

CHEMISTRY

Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

51 API Suppliers

26 USDMF

15 CEP/COS

4 JDMF

13 EU WC

6 KDMF

20 NDC API

26 Listed Suppliers

$ API Reference Price

DEVELOPMENTS

5 Drugs in Development

INTERMEDIATES

5 Intermediates Suppliers

FINISHED DOSAGE FORMULATIONS

386 FDF Dossiers

97 FDA Orange Book

212 Europe

28 Canada

15 Australia

19 South Africa

15 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

INJECTABLE;SUBCUTANEOUS - EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 100MG BASE

TABLET;ORAL - EQ 25MG BASE

TABLET;ORAL - EQ 50MG BASE

SYSTEM;IONTOPHORESIS - EQ 6.5MG BASE/4HR

POWDER;NASAL - EQ 11MG BASE

SPRAY;NASAL - 20MG/SPRAY

SPRAY;NASAL - 5MG/SPRAY

TABLET;ORAL - 500MG;EQ 85MG BASE

TABLET;ORAL - 60MG;EQ 10MG BASE

INJECTABLE;SUBCUTANEOUS - EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML)

INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)

RELATED EXCIPIENT COMPANIES

1 Actylis

1 Finar

EXCIPIENTS BY APPLICATIONS

1 Parenteral

1 Topical

DIGITAL CONTENT

2 DATA COMPILATION #PharmaFlow

34 NEWS #PharmaBuzz

GLOBAL SALES INFORMATION

3 US Medicaid Prescriptions

178 Finished Drug Prices

8 Annual Reports

MARKET PLACE

11 APIs

1 FDF Dossiers

PATENTS & EXCLUSIVITIES

51 US Patents

10 Health Canada Patents

REF. STANDARDS & IMPURITIES

3 EDQM

3 USP

5 Others

Filters

INJECTABLE;SUBCUTANEOUS - EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons